About Altasciences
A Message of Thanks From CEO Chris Perkin
On June 12, Altascientists at all nine of our facilities took time to celebrate each other and the important work that we do as your partners. Altasciences Day, as we like to call it, is a testament to our journey with you—a journey defined by collaboration, dedication, and moving in unison.
I want to extend my heartfelt gratitude for your ongoing trust and partnership, and for giving us the opportunity to help you bring better drugs to the people who need them, faster.
Here’s to many more remarkable accomplishments, and even more reasons to celebrate.
Cheers,
Chris Perkin
CEO, Altasciences
Simpler Clinical Development From Day Dot
Connecting the Dots With Comprehensive CRO Solutions
When you CONNECT THE DOTS, you open a world of possibilities.
At Altasciences, we connect the dots, so you don’t have to. With you in mind, we establish a clear and consistent path from drug discovery to delivery—one solution seamlessly connecting to the next. All you have to do is reach out and get the conversation started.
Ready for a simpler drug development journey? Contact us today.
You may also be interested in these resources:
- Webpage: Clinical Research Support Services
- Video: Clinical Trial Site Identification, Selection, and Management
- Fact Sheet: Comprehensive Research Support Services
Getting to the Heart of Science with Sophie Dubois
The Stories That Inspire
In this video, our very own Sophie Dubois shares what led her to Altasciences and how the company’s core values and mission of helping to improve lives resonate with her.
Optimizing for Success: How Sponsors Can Overcome the Challenges in Early-Phase Drug Development
The Challenges With Outsourcing Drug Development
In a Biopharma Dive survey, 45% of the over 143 biopharmaceutical executives surveyed cited the inability to adhere to tight deadlines as a common challenge in preclinical and Phase I clinical development.
Altasciences Receives 2024 CRO Leadership Award for Capabilities
Laval, Québec, May 29, 2024 – Altasciences announced today that it has been recognized for excellence in contract research with a 2024 CRO Leadership Award for Capabilities. This marks the ninth year that Altasciences, a fully integrated drug development solution company, has been deemed a top performer.
Clinical Leader and Life Science Leader teamed up with ISR Reports to assess 42 CROs on more than 20 performance metrics in ISR’s annual CRO Quality Benchmarking survey. Survey respondents are qualified and only evaluate companies with which they have worked on an outsourced project within the past 18 months.
“For 12 years, Life Science Connect has been working alongside ISR Research to develop our annual CRO Leadership Awards. Receiving one of these awards is a testament to a company’s relentless pursuit of providing the highest standard of service to the clinical research industry, and we congratulate the winners on all their hard work,” said Dan Schell, Chief Editor, Clinical Leader.
The Capabilities category assesses respondents on a CRO’s ability to deliver a wide range of services, expertise, and resources across multiple therapeutic areas. Altasciences has transformed the traditional outsourcing paradigm by building a one-stop outsourcing solution with end-to-end services that simplify and safely accelerate the early-phase drug development process for its clients.
"We are honored to have been recognized as a leader in the CRO industry. Our mission has always been to provide the highest quality early-stage drug development solutions, with personalized services and a focus on efficiency. These awards recognize and validate our employees' daily efforts to achieve our goal. I am incredibly proud of our team," said Chris Perkin, CEO at Altasciences.
With nine strategically placed research and manufacturing facilities across North America, Altasciences helps safely accelerate its clients’ life-changing therapeutics from lead candidate selection to clinical proof of concept, and beyond.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Media Contact
Julie-Ann Cabana
Altasciences
+1 514 601-9763
CNS Breakthroughs: Fuel Your Curious Mind
Cutting-Edge CNS Research and Drug Development
Altasciences’ CNS Center of Excellence has completed over 200 neurological studies, offering you decades of drug development experience. Moreover, our in-house nonclinical, clinical, bioanalytical, and manufacturing teams ensure your compound advances seamlessly from one drug development phase to the next―saving you up to 40% in time.
Dive into our latest resources to uncover groundbreaking insights shaping the future of neuroscience.
Scientific Article
Discover the latest insights on CNS drug development programs and learn how partnering with an end-to-end solution provider can take you seamlessly from lead candidate selection to market.
Scientific Article
Learn about the requirements and technicalities of driving studies, and how driving simulation studies are an effective alternative to on-the-road driving trials for CNS-active drugs.
Complimentary Webinar
Key considerations for clinical drug development of psychedelics, including how to evaluate a drug for abuse potential using an Eight Factor Analysis (8FA), and how best to optimize clinical trials with blinding, control selection, and the role of the facilitator.
Complimentary Webinar
Explore the flexible selection of pharmacodynamic measures to enhance the pharmacology, safety, and efficacy evaluation of a CNS-active drug in early clinical trials.
Ready to get your program started? Speak with one of our experts.
Five Promising Treatment Areas in Early-Phase Drug Development in 2024
Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. In this blog article, we review some of these areas of investigation where Altasciences has robust expertise and solution offerings.
What does change in drug development look like?
Disrupting the CRO Model:
A 2024 Global Health Summit Documentary
Can the drug development industry change for the better?
In a short documentary for the 2024 Global Health Summit, your partners at Altasciences lead the conversation on change in a slow-to-change industry. We dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and sponsors, and how Altasciences has broken from tradition to offer an alternative outsourcing model that can help you bring better drugs to people who need them, faster.
Watch Altasciences in "The Shape of Progress"
Shaping Progress in the Drug Development Industry: A Short Documentary for the 2024 Global Health Summit
Be a part of driving change in global health by safely accelerating your early-phase drug development with Altasciences’ integrated model. Contact us to get started!
What is the Global Health Summit?
The Global Health Summit will be hosted alongside the WHO’s 77th World Health Assembly in Geneva this May. Leading up to the Summit is a series of interviews and documentaries about how the private sector can help drive global health in a positive direction. The campaign highlights several organizations pioneering developments within the healthcare sector. Altasciences is proud to participate in this year’s campaign.
Disrupting the CRO Model: Altasciences Participates in Documentary Series for 2024 Global Health Summit
Altasciences is leading the conversation on change in the drug development industry as part of a new documentary series for the 2024 Global Health Summit, hosted alongside the WHO’s 77th World Health Assembly in Geneva in May. The mini documentary explores transformation in the slow-to-change drug development industry.
Don’t Miss the Latest Life Science Resources
Top 10 Life Science Resources
Your time is precious. Therefore, we’ve curated a selection of recently published expert insights, tips, case studies, and scientific and regulatory information, just for you.
Discover how integrated preclinical and bioanalytical services can benefit your gene therapy requirements, what platforms are available, and what advancements in gene therapy treatments our experts are anticipating. Read the blog.
2. Webinar: Sinclair Nanopig™–The Next Generation, Non-Rodent Model for (Bio)Pharmaceuticals Safety Assessment
Learn about the advantages of factoring miniature swine into your species selection considerations, from cost-efficiency to lower body weight, and comparable toxicological data to beagles and Göttingen minipigs. Watch the webinar.
3. eBook: First-in-Human Solutions for Small and Large Molecules
Explore the benefits of a customized and integrated approach to your first-in-human (FIH) clinical trials. Read the eBook.
4. Webinar: On the Edge of Dermatology Early-Phase Trial
Innovaderm invited Altasciences for a roundtable discussion on the current landscape in early-phase dermatology clinical trials. Discover how these trials are instrumental in shaping innovative treatments and therapeutic strategies for dermatological conditions. Watch the webinar.
5. Fact Sheet: Flow Cytometry Services
Uncover the scope of flow cytometry services available to you when partnering with Altasciences for your immunology and cell-based research. Read now.
6. Podcast: Sparking the Evolution of Microsampling with the Mitra® VAMS® Device
Jeff Plomley, Scientific Director, Method Development, discusses the history and evolution of microsampling with guest Dr. James Rudge, the co-inventor of the Mitra® VAMS® device, and Microsampling Technical Director of Neoteryx. Listen to the podcast.
7. Infographic: Choosing the Optimal Dosage Form for Your Molecule
Discover the advantages of liquid-filled, hard-shell capsules (LFHCs), and tablets, as well as which factors come into play when selecting the appropriate oral dosage form for your active pharmaceutical ingredients (APIs). View the infographic.
8. Ask an Altascientist: The Benefits of Nanomilling
Andrew Buis explains the valuable techniques and equipment utilized in nanomilling—a sophisticated process that breaks down API particles into smaller sizes to enhance their surface area and dissolution rate. Watch here.
9. eBook: Regulatory Comparisons for Starting First-in-Human Clinical Trials
FIH trials are a critical first step for your drug development program. This eBook will show you how conducting Phase I research in North America can shorten timelines by as much as six weeks, in comparison to the EU and UK. Read the eBook to learn more.
10. Case Study: Streamlining Clinical Trial Start-up for Accelerated Drug Development
Learn how Altasciences was able to condense the start-up timeline for a Phase I study from the typical 12 weeks to three and a half, by emphasizing effective communication, strategic planning, and delegation of responsibilities. Read the case study.
Recent Regulatory Updates:
• FDA: Guidance Draft – Early Alzheimer’s Disease: Developing Drugs for Treatment
• FDA: Guidance Final Revision – Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products
• FDA: Guidance Final Revision – Clinical Pharmacology Considerations for Antibody-Drug Conjugates
• FDA: Guidance Final Revision – Gene Therapy Products Incorporating Human Genome Editing
• FDA: Final Rule – Biologics License Applications
• FDA: Guidance Draft – Race and Ethnicity Data Terminology in Clinical Trials
• EMA: Guideline – ICH Q14 Analytical Procedure Development
• EMA: Guideline Revision – Clinical Evaluation of Medicinal Products Intended for Treatment of Hepatitis B